In the last trading session, 1.05 million Cytek BioSciences Inc (NASDAQ:CTKB) shares changed hands as the company’s beta touched 1.21. With the company’s per share price at $2.66 changed hands at -$0.03 or -1.12% during last session, the market valuation stood at $336.91M. CTKB’s last price was a discount, traded about -186.84% off its 52-week high of $7.63. The share price had its 52-week low at $2.52, which suggests the last value was 5.26% up since then.
Analysts gave the Cytek BioSciences Inc (CTKB) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.67. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended CTKB as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Cytek BioSciences Inc’s EPS for the current quarter is expected to be -0.02.
Cytek BioSciences Inc (NASDAQ:CTKB) trade information
Instantly CTKB was in red as seen at the end of in last trading. With action -10.74%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -59.01%, with the 5-day performance at -10.74% in the red. However, in the 30-day time frame, Cytek BioSciences Inc (NASDAQ:CTKB) is -28.11% down.
The consensus price target for the stock as assigned by Wall Street analysts is 6.62, meaning bulls need an upside of 59.82% from its current market value. According to analyst projections, CTKB’s forecast low is 5.25 with 8 as the target high. To hit the forecast high, the stock’s price needs a -200.75% plunge from its current level, while the stock would need to soar -97.37% for it to hit the projected low.
Cytek BioSciences Inc (CTKB) estimates and forecasts
Year-over-year growth is forecast to reach -0.47% down from the last financial year.
Consensus estimates given by 5 financial analysts project the company’s revenue in the current quarter to hit an average of 46.03M. 5 analysts are of the opinion that Cytek BioSciences Inc’s revenue for the current quarter will be 52.18M. The company’s revenue for the corresponding quarters a year ago was 46.62M and 51.5M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -1.25%. The estimates for the next quarter sales put growth at 1.31%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 18.28%. The 2025 estimates are for Cytek BioSciences Inc earnings to decrease by -178.21%.
CTKB Dividends
Cytek BioSciences Inc is expected to release its next quarterly earnings report in June.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 8.9365% or 11.75 million shares worth $65.54 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were iShares Trust-iShares Core S&P Small-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 6.61 shares estimated at $17.58 million under it, the former controlled 5.22% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 2.66% of the shares, roughly 3.37 shares worth around $8.96 million.
